close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

14.44 +0.18 (+1.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
NASDAQ: AUPH Long Term Investor Alert: Investigation of Potential Wrongdoing at Aurinia Pharmaceuticals Inc. ↗
San Diego, CA -- (SBWIRE) -- 08/15/2022 -- Certain directors of Aurinia Pharmaceuticals Inc. are under investigation over possible breaches of fiduciary duties. 
Via SBWire
News headline image
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Last Day to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
AURINIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
AUPH FINAL DEADLINE TUESDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 14 Deadline in Securities Class Action - AUPH
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
NASDAQ:AUPH Investor Notice: Deadline on June 14, 2022 in Lawsuit Against Aurinia Pharmaceuticals Inc. ↗
San Diego, CA -- (SBWIRE) -- 06/08/2022 -- The Shareholders Foundation announced that a deadline is coming up on June 14, 2022 in the lawsuit filed for certain investors of Aurinia Pharmaceuticals Inc.... 
Via SBWire
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
INVESTOR DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPH
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Aurinia Reports First Quarter 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Shareholder Action Alert: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Investor Action Notice: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Investor Action Alert: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today